World's Best Scientists 2026 revealed!
Jean-Jacques Grob

Jean-Jacques Grob

D-Index & Metrics

Medicine

D-Index
103
Citations
86496
World Ranking
7149
National Ranking
218

Overview

Jean-Jacques Grob is affiliated with Aix-Marseille University in France. Their primary research focus lies within the broad field of Medicine, with significant contributions to Oncology, Molecular Biology, Epidemiology, Immunology, and Dermatology.

The scientist's work encompasses various topics related to cancer and immune system research including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Nonmelanoma Skin Cancer Studies
  • Immunotherapy and Immune Responses
  • Cutaneous lymphoproliferative disorders research

Jean-Jacques Grob has authored numerous papers, contributing to the academic literature with a focus on melanoma and immunotherapy. Some of their recent publications include:

  • "Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)," 2020, Journal of Clinical Oncology

While Jean-Jacques Grob authored key clinical trial work in the area of immune checkpoint inhibitors, it is notable that several frequently cited melanoma and immunotherapy papers in their network include:

  • "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma," 2022, Zurich Open Repository and Archive (University of Zurich)
  • "Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial," 2021, The Lancet Oncology
  • "Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial," 2020, Journal of Clinical Oncology
  • "European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022," 2022, European Journal of Cancer

Jean-Jacques Grob frequently collaborates with several coauthors, notable for repeated joint publications, including:

  • Georgina V. Long
  • Paolo A. Ascierto
  • Dirk Schadendorf
  • Caroline Robert
  • Célèste Lebbe

The scientist's publications are commonly featured in well-known oncology and dermatology journals such as:

  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Annals of Oncology
  • Annales de Dermatologie et de Vénéréologie
  • Annales de Dermatologie et de Vénéréologie - FMC

Best Publications

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

    Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

    Mark R Middleton;J J Grob;N Aaronson;G Fierlbeck

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

    Jedd D Wolchok;Bart Neyns;Gerald Linette;Sylvie Negrier

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

    Frank Stephen Hodi;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

  • Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

    Georgina V Long;Reinhard Dummer;Omid Hamid;Thomas F Gajewski

  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Caroline Robert;Antoni Ribas;Jacob Schachter;Ana Arance

  • The role of BRAF V600 mutation in melanoma

    Paolo A. Ascierto;John M. Kirkwood;Jean Jacques Grob;Ester Simeone

Frequent Co-Authors

Caroline Robert
Caroline Robert University of Paris-Saclay
Georgina V. Long
Georgina V. Long University of Sydney
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Axel Hauschild
Axel Hauschild Kiel University
Céleste Lebbé
Céleste Lebbé Hôpitaux Universitaires Paris-Ouest
Piotr Rutkowski
Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Vanna Chiarion-Sileni
Vanna Chiarion-Sileni European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students exploring a future in medicine, a range of online degrees and alternative career pathways are available in the USA. Each offers distinct entry requirements, study durations, and career outcomes, making it important to choose an option that aligns with your personal and professional goals.

Nursing remains one of the most accessible fields, with several nursing schools that don't require teas test. This can streamline admissions for aspiring nurses seeking flexibility or facing exam barriers.

For those interested in the administrative side of healthcare, a health care administration degree online offers an accelerated path to leadership roles in hospitals, clinics, and public health organizations.

Nurses looking to advance can bridge from associate to graduate-level practice with asn to np programs, opening opportunities as nurse practitioners and specialized clinicians.

Nutrition is another vital healthcare field. A flexible option for those interested in dietetics or wellness coaching is a bachelor's in nutrition online, allowing study and professional development on your own schedule.

Best Scientists Citing Jean-Jacques Grob

Trending Scientists